Table 1.
Clinical, demographic, and neuropathological characteristics by diagnosis category
| Clinical Diagnosis |
Comparison by diagnosis group | |||||
|---|---|---|---|---|---|---|
| NCI (N=17) | MCI (N=20) | AD (N=21) | Total (N=58) | |||
| Age at death (years): | Mean ± SD (Range) | 82.8 ± 6.8 (67–92) | 83.6 ± 5.2 (72–92) | 86.3 ± 6.0 (70–97) | 84.3 ± 6.1 (67–97) | p = 0.2a |
| Number (%) of males: | 9 (53%) | 11 (55%) | 9 (43%) | 29 (50%) | p = 0.8b | |
| Years of education: | Mean ± SD (Range) | 18.4 ± 3.5 (12–25) | 18.6 ± 3.6 (8–24) | 17.5 ± 2.9 (8–24) | 18.1 ± 3.3 (8–25) | p = 0.4a |
| Number (%) with ApoE ε4 allele: | 3 (18%) | 4 (20%) | 8 (38%) | 15 (26%) | p = 0.4b | |
| MMSE: | Mean ± SD (Range) | 28.1 ± 1.5 (25–30) | 27.0 ± 2.4 (20–30) | 15.5 ± 7.7 (0–25) | 23.2 ± 7.6 (0–30) | p < 0.0001a* |
| Global Cognitive Score (GCS)§: | Mean ± SD (Range) | 0.56 ± 0.28 (−0.08, 1.15) | 0.26 ± 0.32 (−0.25, 0.83) | −0.83 ± 0.55 (−2.22,−0.26) | −0.02 ± 0.72 (−2.22, 1.15) | p < 0.0001a** |
| Post-mortem interval (hours): | Mean ± SD (Range) | 5.0 ± 2.3 (2.3–11.0) | 6.3 ± 3.7 (2.7–13.9) | 6.5 ± 3.1 (2.7–12.4) | 6.0 ± 3.1 (2.3–13.9) | p = 0.3a |
| Distribution of Braak scores: | I–II | 4 | 3 | 1 | 8 | p = 0.0008a* |
| III–IV | 12 | 15 | 8 | 35 | ||
| V–VI | 1 | 2 | 12 | 15 | ||
| Distribution of NIA Reagan diagnosis (likelihood of AD): | No AD | 0 | 0 | 0 | 0 | p = 0.014a* |
| Low | 7 | 8 | 4 | 19 | ||
| Intermediate | 9 | 11 | 8 | 28 | ||
| High | 1 | 1 | 9 | 11 | ||
| Distribution of CERAD diagnosis (likelihood of AD): | No AD | 4 | 7 | 2 | 13 | p = 0.060a |
| Low | 2 | 1 | 1 | 4 | ||
| Intermediate | 9 | 6 | 8 | 23 | ||
| High | 2 | 6 | 10 | 18 | ||
a
Kruskal-Wallis test.
b
Fisher’s exact test.
*
Pairwise comparisons with Bonferroni correction revealed that there was no significant difference between NCI and MCI, but both were significantly different from AD.
**
Pairwise comparisons with Bonferroni correction showed significant difference between NCI, MCI, and AD.
§
GCS was unavailable for 2 MCI and 3 AD cases.